Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Neurology | Psychiatry/Psychology | Pediatrics/Neonatology | Family Medicine
Disease Category: Attention Deficit/Hyperactivity Disorder (ADHD - Pediatric)
Location: United States, UT

Clinical Trial Details

Overview

Research Study Summary

Adolescent ADHD

Purpose

A Phase 3b, Double-blind, Randomized, Active-controlled, Parallel-group Study to Compare the time to Response of Lisdexamfetamine Dimesylate to Atomoxetine Hydrochloride in Children and Adolescents aged 6-17 years with Attention-Deficit/Hyperactivity Disorder (ADHD) who have Had an Inadequate response to Methylphenidate Therapy.

Patient Inclusion Criteria:

  • Historical or current inadequate response to MPH treatment
  • Male or Female aged 6-17 years

Patient Exclusion Criteria:

  • Subject has taken >1 MPH treatment
  • Subject has previously demonstrated intolerable side effects to 1 or more MPH Treatments
  • Subject has previously been exposed to Strattera or to amphetamine therapy

To Learn more
Phase

3

Gender

Both Male and Female

Age

6 to 17 Years

Overall Status

Recruiting

Facility Type

N/A

Contact

Cher Struck, Director Marketing and Recruiting
Lifetree Clinical Research
3838 South 700 East Suite 202
Salt Lake CIty, UT 84106
Phone: 801-269-8200

View Map

Research Center Information: Lifetree Clinical Research

If you would like to learn more about participating in this research study, please email the trial contact using the form below.

Name:
Address:
City:
State:
Zip/Postal Code:
Country:
Phone:
Email:  
Message:
 
Please leave this field empty.

CW ID: 180847

Date Last Changed: July 19, 2013


DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.